Cite

HARVARD Citation

    Carbery, I. et al. (n.d.). P731 Effect on direct and indirect costs of switching Inflammatory Bowel Disease patients from intravenous to subcutaneous infliximab (CT-P13). Journal of Crohn's and colitis. p. i861. [Online]. 
  
Back to record